Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380178 | 0.85 | PARP1 (0.69) | PARP1PSMD14 | |
| SCHEMBL26523343 | 0.85 | PARP1 (0.53) | PARP1PSMD14KDM4E | |
| SCHEMBL10464539 | 0.83 | PSMD14 (0.67) | PARP1ALDH1A1LMNAALOX12PSMD14 | |
| SCHEMBL17802100 | 0.81 | PARP1 (0.50) | PARP1ALDH1A1LMNAALOX12PSMD14 | |
| SCHEMBL9355371 | 0.81 | PARP1 (0.74) | PARP1ALDH1A1PSMD14KDM4E | |
| SCHEMBL1612627 | 0.81 | PARP1 (0.50) | PARP1ALDH1A1LMNAALOX12PSMD14 | |
| SCHEMBL343891 | 0.81 | PSMD14 (0.51) | PARP1ALDH1A1LMNAPSMD14KDM4E | |
| SCHEMBL28888906 | 0.78 | PARP1 (0.55) | PARP1ALDH1A1LMNAPSMD14KDM4E | |
| SCHEMBL28076889 | 0.77 | PARP1 (0.56) | PARP1ALDH1A1LMNAPSMD14KDM4E | |
| SCHEMBL11429773 | 0.76 | ALDH1A1 (0.58) | PARP1ALDH1A1LMNAALOX12CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651647-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDEA4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | claimed |
| WO-2005010001-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDEA4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | claimed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| CN-116134026-A | Triazole derivatives and their use as tankyrase inhibitors | 奥斯陆大学国家医院 | 2023-05-16 | — | — | CN | disclosed |
| EP-4175952-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | Oslo Universitetssykehus HF (NO) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022008896-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. | GOLDING, LOUISE (GB) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022008896-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. | GOLDING, LOUISE (GB) | 2022-01-13 | — | — | WO | disclosed |
| US-8633220-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7153870-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1651647-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDEA4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005010001-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDEA4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020626-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | PARP1 1472/4885ALDH1A1 2476/4885LMNA 1966/4885 |
| US-20050020626-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PARP1 246/4885ALDH1A1 284/4885LMNA 1730/4885 |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | PARP1 1380/4885ALDH1A1 753/4885LMNA 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.